Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI

Launched by TANTA UNIVERSITY · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a specific type of medication called a non-selective beta-adrenergic blocker in patients with severe traumatic brain injuries (TBI). The goal is to see if this medication can help reduce stress on the brain and improve outcomes for patients who have experienced a serious injury. The trial is currently not recruiting participants, but when it starts, it will focus on adults aged 18 to 65 who have a severe TBI and a low score on the Glasgow Coma Scale, which measures consciousness and responsiveness.

To be eligible for the trial, patients must not have any pre-existing heart issues or certain other medical conditions that would prevent them from safely using the beta-blocker. Participants in the study may receive the medication while being closely monitored in an intensive care unit. This trial is important because it could lead to new treatment options for people with severe brain injuries, potentially improving their chances of recovery and reducing the risk of complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between 18and 65 years old
• • Patients who have Severe traumatic brain injury
• • Glascow outcome scale ≤ 8
• Exclusion Criteria:
• • Patients have pre-existing heart disease.
• • If there are contraindications to β blocker.
• • penetrating traumatic brain injury.
• • pre-injury brain dysfunction.
• • β-blocker or α2-agonist use before trauma.